S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
S&P 500   5,069.53
DOW   39,069.23
QQQ   436.55
Is CRISPR Therapeutics the NVIDIA of gene editing?
Critical asset just had biggest fall on record (Ad)
3 Chinese stocks poised for rebound
4 stocks benefitting from NVIDIA's explosive growth
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
These 2 carnivore dining stocks gaining on the Ozempic craze
This healthcare stock making a buzz with 160% growth
Critical asset just had biggest fall on record (Ad)
First it was Tyson stock, now this food company is set to rally
How major US stock indexes fared Monday, 2/26/2024
NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Price, News & Analysis

$4.35
-0.02 (-0.46%)
(As of 02/26/2024 ET)
Today's Range
$4.22
$4.45
50-Day Range
$3.62
$5.52
52-Week Range
$3.50
$9.25
Volume
152,235 shs
Average Volume
339,254 shs
Market Capitalization
$121.45 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.75

Reviva Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
285.1% Upside
$16.75 Price Target
Short Interest
Healthy
3.01% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.13mentions of Reviva Pharmaceuticals in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.54) to ($0.92) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.43 out of 5 stars

Medical Sector

501st out of 942 stocks

Pharmaceutical Preparations Industry

216th out of 415 stocks


RVPH stock logo

About Reviva Pharmaceuticals Stock (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. The company's lead product candidate is brilaroxazine (RP5063), which is in Phase III clinical trials for use in the treatment of schizophrenia, as well as completed Phase I clinical trials to treat bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder, pulmonary arterial hypertension, and idiopathic pulmonary fibrosis. It is also developing RP1208 that is in pre-clinical development studies for the treatment of depression and obesity. The company was founded in 2018 and is based in Cupertino, California.

RVPH Stock Price History

RVPH Stock News Headlines

RVPH Mar 2024 4.500 put
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
RVPH Mar 2024 3.000 call
RVPH Mar 2024 5.500 put
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
RVPH Jan 2025 7.500 call
RVPH: Raise & RECOVER Results Review
See More Headlines
Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
2/27/2024
Next Earnings (Estimated)
4/04/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RVPH
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$16.75
High Stock Price Target
$20.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+285.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-24,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.60 per share

Miscellaneous

Free Float
19,032,000
Market Cap
$121.45 million
Optionable
Optionable
Beta
-0.01
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report














RVPH Stock Analysis - Frequently Asked Questions

Should I buy or sell Reviva Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RVPH shares.
View RVPH analyst ratings
or view top-rated stocks.

What is Reviva Pharmaceuticals' stock price target for 2024?

4 brokerages have issued twelve-month target prices for Reviva Pharmaceuticals' shares. Their RVPH share price targets range from $12.00 to $20.00. On average, they predict the company's share price to reach $16.75 in the next year. This suggests a possible upside of 285.1% from the stock's current price.
View analysts price targets for RVPH
or view top-rated stocks among Wall Street analysts.

How have RVPH shares performed in 2024?

Reviva Pharmaceuticals' stock was trading at $5.15 at the beginning of 2024. Since then, RVPH shares have decreased by 15.5% and is now trading at $4.35.
View the best growth stocks for 2024 here
.

Are investors shorting Reviva Pharmaceuticals?

Reviva Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 839,800 shares, an increase of 14.7% from the January 15th total of 732,400 shares. Based on an average daily trading volume, of 519,900 shares, the days-to-cover ratio is presently 1.6 days.
View Reviva Pharmaceuticals' Short Interest
.

When is Reviva Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our RVPH earnings forecast
.

How were Reviva Pharmaceuticals' earnings last quarter?

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its earnings results on Monday, November, 15th. The company reported ($0.12) earnings per share for the quarter, topping analysts' consensus estimates of ($0.23) by $0.11.

Who are Reviva Pharmaceuticals' major shareholders?

Reviva Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Armistice Capital LLC (6.32%), Vanguard Group Inc. (3.49%), Citadel Advisors LLC (0.00%), Northern Trust Corp (0.14%), Tower Research Capital LLC TRC (0.14%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc.
View institutional ownership trends
.

How do I buy shares of Reviva Pharmaceuticals?

Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RVPH) was last updated on 2/27/2024 by MarketBeat.com Staff